Drug discovery and development platform using peptoids to block viral transmission. Proof of concept for COVID-19 with two novel peptoids that block the interaction of SARS COV 2 and ACE2 receptor in live mammals. www.majorislife.com
Coronavirus Disease 2019 (COVID-19) remains a global health crisis, despite the development and use of vaccines in certain countries. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, uses its spike protein to bind to the human cell surface receptor angiotensin-converting enzyme 2 (ACE2), which allows the virus to enter the human body. Using our unique cell screening technology, we identified two ACE2-binding peptoid compounds and developed dimeric derivatives (ACE2P1D1 and ACE2P2D1) that effectively blocked spike protein-ACE2 interaction, resulting in the inhibition of SARS-CoV-2 pseudovirus entry into human cells. ACE2P1D1 and ACE2P2D1 also blocked infection by a D614G mutant pseudovirus. More importantly, these compounds do not decrease ACE2 expression nor its enzyme activity (which is important in normal blood pressure regulation), suggesting safe applicability in humans. https://www.mdpi.com/1422-0067/22/16/8963
Our in vivo study using the Syrian Golden Hamster showed no toxicity and histological analysis showed significant lung protection.